CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
Ferdinandos Skoulidis(The University of Texas MD Anderson Cancer Center), Mark G. Woodcock(Medical College of Wisconsin), Tyler F. Stewart(University of California San Diego), Julia Rotow(University of California, San Francisco), Stephanie Schmidt, Jonathan Killam(North Shore University Hospital), Laura Mezquita(Hospital Clínic de Barcelona), Collin M. Blakely(City College of San Francisco), Minh Truong(The University of Texas MD Anderson Cancer Center), Joseph Juan(UCSF Helen Diller Family Comprehensive Cancer Center), Corinne Liu(Memorial Sloan Kettering Cancer Center), Zenta Walther(Yale University), Sally C. M. Lau(University Health Network), Chad V. Pecot(University of North Carolina at Chapel Hill), Ana Galán‐Cobo(The University of Texas MD Anderson Cancer Center), Melina E. Marmarelis(University of Pennsylvania), Sarah B. Goldberg(Yale University), Nadine S. Jahchan(AbbVie (United States)), Chengyin Min(Acetylon Pharmaceuticals (United States)), Pradnya D. Patil(Cleveland Clinic), Kurtis D. Davies(University of Colorado Anschutz Medical Campus), Kurt A. Schalper(Yale University), Christine M. Bestvina(University of Chicago Medicine Comprehensive Cancer Center), Meagan Montesion(Boston Foundation), Yi Yu(Novartis (United States)), Adrian G. Sacher(Princess Margaret Cancer Centre), Kathryn C. Arbour(Memorial Sloan Kettering Cancer Center), Matthias Scheffler(TH Köln - University of Applied Sciences), Fabrizio Tabbò(Ospedale San Pietro Fatebenefratelli), Xuewen Pan(Baylor College of Medicine), Subba R. Digumarthy(Massachusetts General Hospital), Andreas Saltos(Moffitt Cancer Center), Rachael Palmer, Joseph C. Murray(Johns Hopkins University), Anastasios Dimou(Mayo Clinic in Arizona), Catherine A. Shu(Columbia University Irving Medical Center), Regan Memmott(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Justin F. Gainor(Harvard University), Jonathan W. Riess(University of California Davis Medical Center), David Molkentine(The University of Texas MD Anderson Cancer Center), Meghan J. Mooradian(Massachusetts General Hospital), Yu Qian(Center for Excellence in Molecular Cell Science), Mark M. Awad(Memorial Sloan Kettering Cancer Center), Natalie I. Vokes(The University of Texas MD Anderson Cancer Center), Dwight H. Owen(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Xin Sun(The University of Texas MD Anderson Cancer Center), John T. Le(The University of Texas MD Anderson Cancer Center), Haniel A. Araújo(The University of Texas MD Anderson Cancer Center), Rocio Perez Johnson(Memorial Sloan Kettering Cancer Center), Jessica A. Hellyer(Montrose Center)
Cited by 171
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Detection of Mutations in <i>EGFR</i> in Circulating Lung-Cancer Cells
|New England Journal of Medicine|2008|1.6k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k